Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 12/20 | 0.84 |
| ▸ | TEK | Q02763 | 11/20 | 0.84 |
| ▸ | SRC | P12931 | 11/20 | 0.84 |
| ▸ | HCK | P08631 | 8/20 | 0.79 |
| ▸ | KDR | P35968 | 7/20 | 0.79 |
| ▸ | EGFR | P00533 | 4/20 | 0.79 |
| ▸ | FLT3 | P36888 | 4/20 | 0.79 |
| ▸ | ABL1 | P00519 | 3/20 | 0.79 |
| ▸ | FYN | P06241 | 2/20 | 0.79 |
| ▸ | LYN | P07948 | 2/20 | 0.79 |
| ▸ | CSK | P41240 | 2/20 | 0.79 |
| ▸ | BTK | Q06187 | 2/20 | 0.79 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.79 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.79 |
| ▸ | PLK4 | O00444 | 1/20 | 0.79 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.79 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.79 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.79 |
| ▸ | PAK4 | O96013 | 1/20 | 0.79 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30893936 | 1.00 | LCK (0.84) | LCKTEKSRCHCKKDR | |
| SCHEMBL23847515 | 1.00 | LCK (0.84) | LCKTEKSRCHCKKDR | |
| SCHEMBL23847506 | 1.00 | LCK (0.84) | LCKTEKSRCHCKKDR | |
| SCHEMBL30893882 | 1.00 | LCK (0.84) | LCKTEKSRCHCKKDR | |
| SCHEMBL23847509 | 1.00 | LCK (0.84) | LCKTEKSRCHCKKDR | |
| SCHEMBL23854913 | 1.00 | LCK (0.84) | LCKTEKSRCHCKKDR | |
| SCHEMBL23847712 | 1.00 | LCK (0.84) | LCKTEKSRCHCKKDR | |
| SCHEMBL23847522 | 1.00 | LCK (0.84) | LCKTEKSRCHCKKDR | |
| SCHEMBL30893919 | 1.00 | LCK (0.84) | LCKTEKSRCHCKKDR | |
| SCHEMBL30893890 | 1.00 | LCK (0.84) | LCKTEKSRCHCKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11963960-B2 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | FLASH THERAPEUTICS, LLC (US) | 2024-04-23 | — | — | US | disclosed |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2021-09-30 | — | — | US | disclosed |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11963960-B2 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | MCL1, FLT3, ABL1 | LCK 188/4885TEK 622/4885SRC 95/4885 |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | MCL1, FLT3, ABL1 | LCK 188/4885TEK 622/4885SRC 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.